On Jan. 25, biotechnology company Amgen
- Net revenues rose 17.2%, driven by the strong worldwide performance of the company's pharmaceutical products, especially Aranesp and Enbrel.
- The company expects to file for approval of AMG 531 in 2007.
- In the fourth quarter, Amgen repurchased 3.3 million shares at a total cost of $245 million, with full-year repurchases totaling 70.2 million shares at a total cost of $5 billion. In December, the company's board approved a new $5 billion share repurchase plan.
- The company expects the total revenues for 2007 to be in the range of $15.4 billion to $16 billion and adjusted EPS to be in the range of $4.30 to $4.50.
- Amgen is a four-star stock in Motley Fool CAPS.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$3,835 |
$3,271 |
17.2% |
|
Net Profit |
$833 |
$824 |
1.1% |
|
EPS |
$0.71 |
$0.66 |
7.6% |
|
Diluted Shares |
1,180 |
1,243 |
(5.1%) |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
85.4% |
84.4% |
1.0 |
|
Operating Margin |
25.8% |
33.7% |
(7.9) |
|
Net Margin |
21.7% |
25.2% |
(3.5) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$6,277 |
$5,255 |
19.4% |
|
Accounts Rec. |
$2,124 |
$1,769 |
20.1% |
|
Inventory |
$1,903 |
$1,258 |
51.3% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$5,144 |
$3,595 |
43.1% |
|
Long-Term Debt |
$7,134 |
$3,957 |
80.3% |
Learn the ways of the balance sheet.
Cash Flow Highlights
Amgen didn't provide cash-flow data. Boo!
Find out why Fools always follow the money.
Related Companies:
-
Genentech
(NYSE:DNA) -
Gilead Sciences
(NASDAQ:GILD) -
Celgene
(NASDAQ:CELG) -
Genzyme
(NASDAQ:GENZ) -
Biogen Idec
(NASDAQ:BIIB)
Related Foolishness:
Biogen Idec is a Motley Fool Stock Advisor recommendation. To find out why, you can take a 30-day free trial of the newsletter.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
